Filing Flows

Filing Flows › Companies › Kestra Medical Technologies › Cash flow

Kestra Medical Technologies cash flow, quarter by quarter

Latest: Q1 FY27 · from the cash-flow statements filed with the SEC

Free cash flow−$40.6M in Q1 FY27 · −$123M over twelve months

Operating cash flow−$32.3M
Capital spending−$8.3M
Free cash flow−$40.6M
Cash conversion cycle-137 days

Analysis

In Q1 FY27, Kestra Medical Technologies generated −$32.3M of operating cash flow and spent $8.3M on capital projects, leaving free cash flow of −$40.6M. That is $6.2M less than in Q1 FY26 (−$34.4M).

Over the twelve months to Jul 31, 2026, operating cash flow was −$87.7M; the largest uses were other investing ($181M), operating cash flow ($87.7M), capital spending ($35.1M); besides operations, cash came from other financing ($171M); the cash balance fell by $133M.

Operating cash flow was −$32.3M against net income of −$44.1M. The largest differences: stock-based pay +$9.5M, accrued liabilities −$4.7M, depreciation & amortization +$2.7M.

Its cash conversion cycle was -137 days (receivables 44 + inventory 0 − payables 182): suppliers fund its working capital.

Free cash flow

Kestra Medical Technologies: free cash flow by quarterKestra Medical Technologies: free cash flow by quarter−$22.5MQ2 FY25−$22.1MQ3 FY25−$31.4MQ4 FY25−$34.4MQ1 FY26−$25.6MQ2 FY26−$28.2MQ3 FY26−$28.4MQ4 FY26−$40.6MQ1 FY27
Operating cash flow less capital spending.
Kestra Medical Technologies: operating cash flow against capital spendingKestra Medical Technologies: operating cash flow against capital spendingOperating cash flowCapital spending−$18.1M$4.4MQ2 FY25−$18.0M$4.1MQ3 FY25−$24.1M$7.4MQ4 FY25−$26.3M$8.2MQ1 FY26−$18.3M$7.3MQ2 FY26−$18.4M$9.8MQ3 FY26−$18.7M$9.7MQ4 FY26−$32.3M$8.3MQ1 FY27
Latest (Q1 FY27): Operating cash flow −$32.3M, Capital spending $8.3M.

Capital allocation, year by year

Kestra Medical Technologies: where the cash came from (up) and went (down), by fiscal yearKestra Medical Technologies: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingFY24: Operating cash flow −$72.2MFY24: Net borrowing $5.9MFY24: Capital spending −$12.2M$5.9MFY24FY25: Operating cash flow −$77.6MFY25: Shares issued $216MFY25: Capital spending −$22.9M$216MFY25FY26: Operating cash flow −$81.7MFY26: Shares issued $150MFY26: Capital spending −$34.9M$150MFY26
Over these 3 years operating cash flow totalled −$232M; the largest uses were operating cash flow ($232M) and capital spending ($70.1M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$199M
Debt$72.5M
Net cash$126M
Cash runway19 months

Kestra Medical Technologies is burning cash: its operations consume cash, a free cash flow of −$123M a year at the current rate against $199M of cash and investments: a runway of about 19 months before any new financing.

Where the cash came from and went

Kestra Medical Technologies: sources (+) and uses (−) of cash, Q1 FY27Kestra Medical Technologies: sources (+) and uses (−) of cash, Q1 FY27Operating cash flow−$32.3MCash drawn (+) / kept (−)$31.2MNet borrowing (+) / repaid (−)$28.6MOther investing−$13.0MCapital spending−$8.3MOther financing−$7.2MShares issued$1.1M
Kestra Medical Technologies: sources (+) and uses (−) of cash, TTM to Q1 FY27Kestra Medical Technologies: sources (+) and uses (−) of cash, TTM to Q1 FY27Other investing−$181MOther financing$171MCash drawn (+) / kept (−)$133MOperating cash flow−$87.7MCapital spending−$35.1M

From profit to cash

Kestra Medical Technologies: net income to operating cash flow, Q1 FY27Kestra Medical Technologies: net income to operating cash flow, Q1 FY27Net income−$44.1MDepreciation & amortization$2.7MStock-based pay$9.5MGains on disposals$292KReceivables−$48KPayables−$1.9MAccrued liabilities−$4.7MPrepaid and other assets$246KOperating cash flow−$32.3M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q1 FY2744—182-137
Q4 FY2642—176-134
Q3 FY2643—175-131
Q2 FY2640—160-120
Q1 FY2641—186-145

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q1 FY27−$32.3M−$8.3M$28.6M$1.1M$31.2M−$40.6M
Q4 FY26−$18.7M−$9.7M——$192M−$28.4M
Q3 FY26−$18.4M−$9.8M——−$116M−$28.2M
Q2 FY26−$18.3M−$7.3M——$25.8M−$25.6M
Q1 FY26−$26.3M−$8.2M——$36.4M−$34.4M
Q4 FY25−$24.1M−$7.4M——−$183M−$31.4M
Q3 FY25−$18.0M−$4.1M——$22.6M−$22.1M
Q2 FY25−$18.1M−$4.4M——$23.1M−$22.5M

Kestra Medical Technologies: income statement and cash flow

Kestra Medical Technologies, Q1 FY27: revenue $31.0M (+60% year over year), operating margin -121.6%. The chart follows the revenue to costs, profit and cash.

Kestra Medical Technologies: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.